Volume | 4,590,576 |
|
|||||
News | - | ||||||
Day High | 1.62 | Low High |
|||||
Day Low | 1.5311 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Perspective Therapeutics Inc | CATX | AMEX | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.58 | 1.5311 | 1.62 | 1.58 | 1.60 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
12,225 | 4,590,576 | $ 1.57 | $ 7,228,394 | - | 0.205 - 1.77 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
20:00:00 | 95,602 | $ 1.58 | USD |
Perspective Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
448.91M | 280.57M | - | 1.43M | -46.51M | -0.17 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Perspective Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CATX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.44 | 1.77 | 1.3597 | 1.62 | 5,143,963 | 0.17 | 11.81% |
1 Month | 1.25 | 1.77 | 1.15 | 1.48 | 6,469,104 | 0.36 | 28.80% |
3 Months | 0.823 | 1.77 | 0.7178 | 1.27 | 4,076,684 | 0.787 | 95.63% |
6 Months | 0.2611 | 1.77 | 0.2201 | 1.08 | 2,547,079 | 1.35 | 516.62% |
1 Year | 0.52 | 1.77 | 0.205 | 0.9377745 | 1,611,000 | 1.09 | 209.62% |
3 Years | 0.3763 | 1.77 | 0.205 | 0.9111457 | 1,477,952 | 1.23 | 327.85% |
5 Years | 0.3763 | 1.77 | 0.205 | 0.9111457 | 1,477,952 | 1.23 | 327.85% |
Perspective Therapeutics Description
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company. The Company is engaged in the advancement of treatment applications for cancers throughout the body. It is a producer of Cesium-131 brachytherapy seeds. These seeds are designed to treat a variety of cancers including prostate cancer, head and neck, lung and brain. The Company has also developed a lead-212 generator to secure isotope supply for clinical trials and commercial operations. Its lead-212 generator utilizes the isotope lead-212 to deliver alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also engaged in the development of imaging diagnostics (Pb-203 (Lead-203)). The Company¿s melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are under Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at various academic institutions. |